SCHEMBL12124658

SCHEMBL12124658

NC1CCN(c2ncccc2[N+](=O)[O-])CC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.71
CYP2C9 P11712 2/20 0.71
CYP2C19 P33261 1/20 0.71
ALDH1A1 P00352 5/20 0.70
LMNA P02545 3/20 0.66
MAPT P10636 6/20 0.64
MAPK1 P28482 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.59
POLB P06746 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
HSD11B1 P28845 1/20 0.54
NPSR1 Q6W5P4 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
GRM5 P41594 4/20 0.52
HTT P42858 2/20 0.50
GAA P10253 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3280808 0.99 CYP1A2 (0.69) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL8299965 0.92 CYP1A2 (0.63) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL781659 0.86 CYP1A2 (0.87) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL29445475 0.86 CYP1A2 (0.71) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL8259130 0.86 CYP1A2 (0.71) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL3436165 0.86 ALDH1A1 (0.74) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL14377392 0.86 CYP1A2 (0.71) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL12124666 0.85 CYP1A2 (0.66) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL2078675 0.84 MAPT (0.72) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA
SCHEMBL18951797 0.83 CYP1A2 (0.68) CYP1A2CYP2C9CYP2C19ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1882568-B Pyrrol derivatives with antibacterial activity ASTRAZENECA AB 2012-03-28 CN disclosed
US-8058292-B2 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. (US) 2011-11-15 US disclosed
US-8058292-B2 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. (US) 2011-11-15 US disclosed
US-20100256111-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN PURDUE PHARMA L.P. (US) 2010-10-07 US disclosed
US-20100256111-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN PURDUE PHARMA L.P. (US) 2010-10-07 US disclosed
US-7767699-B2 Therapeutic agents useful for treating pain PURDUE PHARMA, L.P. (US) 2010-08-03 US disclosed
US-7767699-B2 Therapeutic agents useful for treating pain PURDUE PHARMA, L.P. (US) 2010-08-03 US disclosed
CN-1882568-A Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-12-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256111-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN CHRNA10, ACHE, SNCA CYP1A2 2596/4885CYP2C9 2716/4885CYP2C19 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.